
Sign up to save your podcasts
Or


Send us Fan Mail
Manal Abdelmalek joins the Surfers to share expectations in advance of Friday's FDA Webcast on NASH Drug Development.
FDA's Friday webcast titled "Regulatory Perspectives for Development of Drugs for Treatment of NASH" is the agency's long-awaited public event to provide better definition on what trial must achieve for a NASH drug to gain approval. In advance of that event, Stephen, Louise, Manal and Roger share expectations for that session. Kitty Yale, Chief Development Officer for Akero Therapeutics and a participant in our post-session podcast, sends in four points to explore. Whether you care about the process of drug development or simply the results in terms of drug approvals, you will find this episode a thought-provoking prequel to the actual event.
By SurfingNASH.com3.9
2424 ratings
Send us Fan Mail
Manal Abdelmalek joins the Surfers to share expectations in advance of Friday's FDA Webcast on NASH Drug Development.
FDA's Friday webcast titled "Regulatory Perspectives for Development of Drugs for Treatment of NASH" is the agency's long-awaited public event to provide better definition on what trial must achieve for a NASH drug to gain approval. In advance of that event, Stephen, Louise, Manal and Roger share expectations for that session. Kitty Yale, Chief Development Officer for Akero Therapeutics and a participant in our post-session podcast, sends in four points to explore. Whether you care about the process of drug development or simply the results in terms of drug approvals, you will find this episode a thought-provoking prequel to the actual event.

32,110 Listeners

30,680 Listeners

9,628 Listeners

103 Listeners

21,136 Listeners

3,365 Listeners

112,075 Listeners

56,533 Listeners

9,527 Listeners

8,018 Listeners

10,193 Listeners

6,389 Listeners

0 Listeners

425 Listeners

741 Listeners